Abstract Number: VPB0319
Meeting: ISTH 2022 Congress
Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » ADAMTS13 and TTP
Background: Rituximab is one of the second-line treatments for ITP. At present, there are few studies on low-dose rituximab, lacking of a large number of prospective and randomized trials to support the efficacy and safety of low-dose rituximab, especially in children’s ITP. Influenced by COVID-19, we used two low-dose rituximab regimens before and after March 2020 for second-line treatment of children’s ITP.
Aims: To compare the efficacy and safety of two different regimens for low-dose rituximab of children patients with chronic /refractory ITP, so as to provide basis for clinical treatment.
Methods: 83 children patients were enrolled in this study and non-randomly assigned to receive 100mg/200mg (body weight 30kg) rituximab weekly for 4 weeks (group A, 53 cases) or a single dose of 375mg / m2 rituximab (group B, 30cases). The study was follow-up for at least half a year.
Results: The baseline data of group A and B were the same. For group A: Overall and complete response (OR and CR) rates were 35.8% and 15%, respectively; the side effects rate is 3.8%. In responders, the median time to response was 4 (1 -12) weeks, with a median follow-up time of 36 (14 ~ 46) months, 6 of 19 responders (31.6%) relapsed. For group B: OR and CR rates were 36.7% and 23%, respectively; the side effects rate is 10%. In responders, the median time to response was 1 (1 ~ 4) weeks, with a median follow-up time of 12(6 ~ 19) months, 4 of 11 responders (36.4%) relapsed. No significant difference in the OR, NR, relapse free survival and incidence of side effects was observed in patients between the two groups.
Conclusion(s): The two low-dose rituximab regimens in the treatment of ITP in children both are safe and effective；The single-agent scheme is more recommended because of easier use and not increasing safety events.
image
The efficacy of two groups
image
The side effect of two groups
To cite this abstract in AMA style:
Zhu X. Efficacy and safety of two different low-dose rituximab regimens for Chinese children patients with primary immune thrombocytopenia [abstract]. https://abstracts.isth.org/abstract/efficacy-and-safety-of-two-different-low-dose-rituximab-regimens-for-chinese-children-patients-with-primary-immune-thrombocytopenia/. Accessed September 21, 2023.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/efficacy-and-safety-of-two-different-low-dose-rituximab-regimens-for-chinese-children-patients-with-primary-immune-thrombocytopenia/